Empirical Asset Management LLC Buys New Stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Empirical Asset Management LLC purchased a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 51,614 shares of the biopharmaceutical company’s stock, valued at approximately $12,145,000.

A number of other institutional investors also recently added to or reduced their stakes in the stock. Gateway Investment Advisers LLC lifted its position in shares of Alnylam Pharmaceuticals by 19.8% during the 4th quarter. Gateway Investment Advisers LLC now owns 7,383 shares of the biopharmaceutical company’s stock worth $1,737,000 after buying an additional 1,222 shares during the period. Burney Co. raised its stake in Alnylam Pharmaceuticals by 22.9% during the fourth quarter. Burney Co. now owns 25,738 shares of the biopharmaceutical company’s stock worth $6,056,000 after acquiring an additional 4,791 shares in the last quarter. Park Avenue Securities LLC lifted its holdings in shares of Alnylam Pharmaceuticals by 64.8% during the fourth quarter. Park Avenue Securities LLC now owns 1,368 shares of the biopharmaceutical company’s stock valued at $322,000 after acquiring an additional 538 shares during the period. Assenagon Asset Management S.A. boosted its stake in shares of Alnylam Pharmaceuticals by 13.0% in the 4th quarter. Assenagon Asset Management S.A. now owns 19,918 shares of the biopharmaceutical company’s stock valued at $4,687,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Pallas Capital Advisors LLC boosted its stake in shares of Alnylam Pharmaceuticals by 2.6% in the 4th quarter. Pallas Capital Advisors LLC now owns 3,408 shares of the biopharmaceutical company’s stock valued at $802,000 after purchasing an additional 87 shares in the last quarter. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, CMO Pushkal Garg sold 1,682 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $422,148.36. Following the transaction, the chief marketing officer now directly owns 17,457 shares of the company’s stock, valued at $4,381,357.86. This trade represents a 8.79 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, EVP Tolga Tanguler sold 1,469 shares of the company’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the sale, the executive vice president now owns 13,191 shares of the company’s stock, valued at approximately $3,310,677.18. This represents a 10.02 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,122 shares of company stock valued at $2,540,455 in the last ninety days. 1.50% of the stock is owned by insiders.

Alnylam Pharmaceuticals Price Performance

ALNY opened at $249.16 on Friday. The company has a fifty day moving average price of $247.25 and a two-hundred day moving average price of $259.68. The company has a debt-to-equity ratio of 31.64, a quick ratio of 2.69 and a current ratio of 2.75. The firm has a market capitalization of $32.14 billion, a PE ratio of -95.10 and a beta of 0.34. Alnylam Pharmaceuticals, Inc. has a 52 week low of $141.98 and a 52 week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($0.87) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.36). The company had revenue of $500.90 million during the quarter, compared to analyst estimates of $532.91 million. During the same period in the previous year, the business posted $1.15 earnings per share. The firm’s revenue for the quarter was down 33.3% compared to the same quarter last year. As a group, analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -2.21 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of brokerages recently issued reports on ALNY. Piper Sandler reiterated an “overweight” rating and set a $296.00 target price on shares of Alnylam Pharmaceuticals in a research report on Monday, November 18th. Scotiabank lifted their target price on shares of Alnylam Pharmaceuticals from $305.00 to $310.00 and gave the company a “sector outperform” rating in a research note on Friday, November 1st. Needham & Company LLC reissued a “buy” rating and issued a $320.00 target price on shares of Alnylam Pharmaceuticals in a report on Monday. Bank of America raised their price target on Alnylam Pharmaceuticals from $307.00 to $314.00 and gave the company a “buy” rating in a report on Monday, October 14th. Finally, Sanford C. Bernstein reduced their price objective on Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and nineteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $298.61.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.